skip to main content

United Therapeutics Corporation To Present At 36th Annual J.P. Morgan Healthcare Conference

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 28, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California.

The presentation and the immediately following Q&A session will take place on Monday, January 8, 2018, at 1:30 PM Pacific Standard Time, and can be accessed via a live webcast on the United Therapeutics website at http://www.unither.com under the "Investors" tab in the "Events and Presentations" section. An archived, recorded version of the presentation and the Q&A session will be available approximately twenty-four hours after the Q&A session ends and can be accessed at the same location for 90 days. [uthr-g]

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions.

 

Cision View original content:http://www.prnewswire.com/news-releases/united-therapeutics-corporation-to-present-at-36th-annual-jp-morgan-healthcare-conference-300575499.html

SOURCE United Therapeutics Corporation

Recent Press Releases

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company will utilize the remainder of...
Nebulized Tyvaso® (treprostinil) Inhalation Solution will be the first and only inhaled anti-fibrotic treatment for idiopathic pulmonary fibrosis (IPF) if approved by the U.S. Food and Drug Administration (FDA) ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that company executives will provide overviews and updates during fireside chat...
ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening in PAH patients...
Ralinepag has the potential to redefine the PAH treatment landscape as the first and only once-daily oral prostacyclin, if approved by the U.S. Food and Drug Administration (FDA)Ralinepag combines potent receptor...
Approximately 200,000 patients in the United States have PPF, with limited treatment optionsTopline data expected in the second half of 2027SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United...